Piper Jaffray analyst Adam Maeder says media reports indicate Congress has a deal in principle that will permanently repeal rather than defer three major health industry taxes, with the device tax being one of them. The analyst tells investors in a research note that if repealed entirely, the issue would no longer surface every year or two causing uncertainty for the space, adding that only Intuitive Surgical has provided guidance which assumed the device tax would be implemented. He says those with the greatest U.S. exposure would benefit the most from an outright repeal, but no one had been paying taxes recently, so there is no upside coming from an outright repeal. The analyst keeps an Overweight rating and $633 price target on Intuitive Surgical shares.